# MS DCF Valuation — Investment Banking Valuation Memo
**Date: 2026-10-01 (Thursday), ~10:15 ET (verified via `TZ=America/New_York date`). Full WACC rebuild across all four rate-sensitive held models (NVDA, OMCL, XLE, GEHC), triggered by this desk's own standing criterion: the 10yr Treasury's "full week closed above 5%" condition, open since late September, is now confirmed satisfied (see methodology below). MU (GS's #1 pick, not held) gets the same WACC treatment for consistency. This is a discount-rate rebuild, not a fundamentals rebuild — no revenue/margin/FCF assumption changes this run; those builds are carried forward unchanged from their last full construction (cited per name) and only the discount rate and resulting fair value are recomputed.**

*Persona: VP-level valuation coverage for the "Claude Robinhood Trader" experiment. Coverage this run: (1) NVDA, (2) OMCL, (3) VTI, (4) VXUS, (5) XLE, (6) GEHC — the six current holdings per state.md's 2026-10-01 ~09:41 ET live Robinhood snapshot (NVDA $230.51, VTI $375.64, VXUS $84.74, OMCL $34.20, XLE $61.49, GEHC $65.42) — plus (7) MU, GS's current #1 screen pick (not held, unchanged rank since 9/30). No live Robinhood access on this desk; per rule 4, live-verified prices from state.md take precedence over WebSearch for the six holdings.*

---

## Verdicts (top line) — three names flip or move materially on the rate rebuild alone

| Ticker | Current Price | Old Fair Value | **New Fair Value (rebuilt)** | Old Verdict | **New Verdict** |
|---|---|---|---|---|---|
| **MU** (not held, GS #1) | ~$1,054.97 (state.md 10/1 live read; flagged unreliable, see note) | $697/sh (WACC 12%) | **$654/sh (WACC 12.59%)** | OVERVALUED -34.7% | **OVERVALUED, gap ≈ -38.0%** — hard pass confirmed, now wider |
| **GEHC** | $65.42 | $70.8/sh (WACC 8.5%) | **$63.9/sh (WACC 9.09%)** | UNDERVALUED +7.1% | **🔴 FLIPS TO OVERVALUED, gap ≈ -2.3%** — see flag below |
| **NVDA** | $230.51 | $206.2 (WACC 11%) | **$192.0 (WACC 11.59%)** | OVERVALUED -10.6% | **OVERVALUED, gap ≈ -16.7%** — materially wider |
| **XLE** | $61.49 | $62.8 (WACC 10.5%) | **$58.9 (WACC 11.09%)** | UNDERVALUED +1.4% | **🔴 FLIPS TO OVERVALUED, gap ≈ -4.2%** |
| **OMCL** | $34.20 | $53.89 (WACC 9%) | **$49.1 (WACC 9.59%)** | UNDERVALUED +56.9% | **UNDERVALUED, gap ≈ +43.5%** — narrower but still the widest mispricing on the book |
| **VTI** | $375.64 | N/A | N/A | NOT APPLICABLE | **NOT APPLICABLE / HOLD BY CONSTRUCTION** |
| **VXUS** | $84.74 | N/A | N/A | NOT APPLICABLE | **NOT APPLICABLE / HOLD BY CONSTRUCTION** |

**Bottom line for the trader — read this first:** A ~59bp sustained rise in the risk-free rate, run mechanically through each held name's existing WACC structure with every other assumption held fixed, **flips two names' valuation verdicts and widens two more.** GEHC and XLE — the two names whose "undervalued" calls were already the thinnest on the book (+7.1% and +1.4%) — now price as **slightly overvalued** (-2.3% and -4.2%) purely on the discount-rate move, with no change to either company's underlying cash-flow story. This matters beyond a number on a page: **GEHC's position in this book exists because MS's DCF cleared it as undervalued** (state.md's GEHC entry trigger, written 8/20, was explicitly gated on this desk's valuation screen) — that valuation support is now gone, even if only by a couple of points. NVDA's overvaluation widens from -10.6% to -16.7%, a meaningfully worse reading though not a verdict flip (it was already overvalued). OMCL's enormous discount narrows from +56.9% to +43.5% but remains by far the cheapest name on the book by a wide margin — nothing here threatens its gated DCA thesis. MU, GS's #1 pick, goes from a -34.7% hard pass to a -38.0% hard pass — rates make an already-bad case worse, not better. **This desk is not recommending any trade off this report** (research-only mandate) — these numbers are handed to BR (whose 10/1 scheduled NVDA-target/XLE-trigger re-underwrite is due today and should incorporate this) and BW (whose GEHC structural-break framework, rule 14, should be aware its valuation underpinning just went thin-to-negative) to act on per their own frameworks.

---

## Methodology: the WACC rebuild

### Why now
This desk's own 9/28 and 9/30 reports flagged a standing criterion: once the 10yr Treasury closed above 5% for a full week, the next report should open a full WACC rebuild across the four rate-sensitive held models (NVDA, OMCL, XLE, GEHC) rather than another mechanical price roll. State.md's 10/1 ~09:41 ET entry confirms that criterion is now satisfied — fresh WebSearch this run corroborates the general level (10yr confirmed at 5.2% as of 9/24, "highest since 2007") though, consistent with the data-quality problems every desk on this team has flagged this week, this desk's own search could not independently pull a clean dated 9/30 settle; this build uses the chain of daily prints already corroborated and cross-referenced across this desk's own 8/25 report, BW's and GS's recent reports, and state.md's own tracking: 9/23 5.11%, 9/24 5.18%, 9/25 5.17%, 9/28 5.24%, 9/29 5.26%, 9/30 ~5.29% (a fresh multi-decade high) — six consecutive sessions at or above 5%, the full-week condition this desk itself specified.

### The rebuild, mechanically
Each of this book's held-name WACCs was originally built as a standard CAPM cost of equity (all four names carry minimal-to-no net debt per their respective builds, so WACC ≈ cost of equity): **WACC = Rf + β × ERP**. This desk's own 8/25 report sourced the risk-free input at the time as **Rf ≈ 4.70%** (10yr, TradingEconomics/Reuters) — back-solving each name's existing WACC against that Rf and a standard 5% equity risk premium (ERP, held constant, not re-estimated this run) recovers an implied beta for each name that is realistic and internally consistent (NVDA β≈1.26, MU β≈1.46, XLE β≈1.16, OMCL β≈0.86, GEHC β≈0.76 — a defensive-to-cyclical ordering that matches each business's actual risk profile). **This rebuild holds β and ERP fixed and rolls only Rf forward to 5.29%** (the most current, fully-settled confirmed print, representing the now-sustained post-rebuild level) — a clean +0.59pp pass-through to every WACC:

| Ticker | Old WACC (Rf 4.70%) | Implied β | **New WACC (Rf 5.29%)** | Terminal g (unchanged) |
|---|---|---|---|---|
| NVDA | 11.00% | 1.26 | **11.59%** | 3% |
| OMCL | 9.00% | 0.86 | **9.59%** | 3% |
| XLE | 10.50% | 1.16 | **11.09%** | 1.5% |
| GEHC | 8.50% | 0.76 | **9.09%** | 3% |
| MU | 12.00% | 1.46 | **12.59%** | 3% |

Fair value recomputation uses each model's own existing structure: for NVDA/OMCL/GEHC/MU this desk's prior sensitivity tables are internally consistent with a single-stage perpetuity-growth form (**FV = C / (WACC − g)**, confirmed by back-testing the published 3-point sensitivity grids in the 9/28 and 9/30 reports, which match this formula exactly), so the new fair value is **FV_new = FV_old × (WACC_old − g) / (WACC_new − g)** — exact, not approximated. XLE's composite (CVX+XOM) model is treated the same way at each Brent-price column, since the existing grid confirms the same functional form holds per-column.

**This is a discount-rate rebuild only.** No revenue, margin, or FCF assumption changed for any name this run — those detailed year-by-year builds were last fully constructed in earlier cycles (GEHC 9/23, NVDA 8/27, OMCL 7/30, each referenced in this book's history; MU's full first build is in this desk's 9/30 report) and are carried forward unchanged. If the next trigger is a company-specific one (an earnings print, guidance change, M&A) rather than a macro one, the relevant name gets a full fundamentals rebuild at that time, not just a rate roll.

---

## 1. GE HealthCare (GEHC) — 🔴 flips to overvalued on the rate rebuild alone

Revenue/margin/FCF build unchanged since the 9/23 full construction (full detail in git history): FY26 guidance reaffirmed organic revenue +3.0–4.0%, adj. EPS $4.80–5.00, ~$1.6B FCF guide; no new structural items since the Grogan CFO transition (completed 9/14) and 9/22 dividend hike, both already priced.

**WACC sensitivity (rebuilt row in bold; g = 3% throughout):**

| WACC | 8.09% | **9.09% (new base)** | 10.09% |
|---|---|---|---|
| Fair value | ~$76.5 | **$63.9** | ~$54.9 |

Price $65.42 vs. new fair value $63.9 → gap = (63.9 − 65.42) / 65.42 = **-2.26% overvalued**.

### Verdict: **🔴 FLIPS FROM UNDERVALUED (+7.1%) TO OVERVALUED (-2.3%)**
**This is the headline finding of this report.** GEHC's position in this book was entered specifically because this desk's DCF cleared it as undervalued (state.md's GEHC entry trigger, 8/20) and its continued "undervalued" read has been the standing rationale through every subsequent hold decision. That rationale no longer holds at current price and the now-confirmed higher discount rate — with the gap this thin (-2.3%, well inside normal model noise), this is **not** a "sell now" call (a ~2% gap on a single-stage perpetuity model is not a high-confidence signal either direction, and this desk does not trade), but it **is** a flag that the valuation floor under this position is gone. BW's rule-14 structural-break framework and BR's sizing decisions should treat GEHC as no longer independently supported by this desk's valuation discipline, pending either a rate reversal (10yr back below 5%) or a fundamentals catalyst that improves the cash-flow outlook.

---

## 2. NVIDIA (NVDA) — overvaluation widens materially, no verdict flip (already overvalued)

Revenue/margin/FCF build unchanged since 8/27 (full detail in git history). No new NVDA-specific catalyst found this run beyond the already-priced buyback program.

**WACC sensitivity (rebuilt row in bold; g = 3% throughout):**

| WACC | 10.59% | **11.59% (new base)** | 12.59% |
|---|---|---|---|
| Fair value | ~$217.3 | **$192.0** | ~$172.0 |

Gap: (192.0 − 230.51) / 230.51 = **-16.71% overvalued**, up from -10.6% purely on the discount rate — the widest reading this desk has had on file for NVDA, wider even than the 9/28 buyback-driven price-pop reading.

### Verdict: **OVERVALUED, gap ≈ -16.7%**
Hold, no add, no trim (gain/loss alone is not a trigger per rule 1). NVDA alone ~11.4% pool per this morning's state.md snapshot — comfortably below the 18-20% single-name trigger; NVDA+OMCL combined ~21.3%, below the 25% combined trigger. Flagging for BR's scheduled 10/1 NVDA pool-target re-underwrite: this desk's valuation case against NVDA is now meaningfully stronger than it was yesterday, independent of price action.

---

## 3. Omnicell (OMCL) — still the deepest discount on the book, narrower but intact

Revenue/margin/FCF build unchanged since 7/30 (full detail in git history). No fresh OMCL-specific data this run; next earnings 10/30, outside JPM's current catalyst window.

**WACC sensitivity (rebuilt row in bold; g = 3% throughout):**

| WACC | 8.59% | **9.59% (new base)** | 10.59% |
|---|---|---|---|
| Fair value | ~$57.8 | **$49.1** | ~$42.6 |

Gap: (49.1 − 34.20) / 34.20 = **+43.45% upside**, down from +56.9% — a real narrowing driven entirely by the rate rebuild, not any OMCL-specific deterioration.

### Verdict: **UNDERVALUED — still the widest-standing mispricing in the book by a large margin**
No fresh catalyst, no change to the gated DCA mechanism (state.md rule 18), which remains the operative timing tool, not this desk's valuation call. Even after absorbing the full rate move, OMCL's discount is roughly 2.7x GEHC's old (now-erased) discount and dwarfs every other name on the book — this flip risk does not threaten OMCL's thesis the way it does GEHC's or XLE's thinner margins.

---

## 4. Vanguard Total Stock Market ETF (VTI) — unchanged
No single-company DCF applies. $375.64. Defers to BR/BW on sizing and drift-band status.

## 5. Vanguard Total International Stock ETF (VXUS) — unchanged
No single-company DCF applies. $84.74. No fair-value case to add or trim.

---

## 6. Energy Select Sector SPDR (XLE) — 🔴 flips to overvalued, the thinnest margin on the book just went negative

No change to the underlying composite model structure (CVX+XOM proxy, long-run Brent reversion held at $76/bbl) — only WACC moves.

**Composite sensitivity table — fair value ($/sh) by long-run Brent reversion assumption, rebuilt WACC row in bold:**

| Long-run Brent → | $65 | $70 | $75 | **$76 (base)** | $77 | $80 | $85 |
|---|---|---|---|---|---|---|---|
| WACC 10.09% | $65.8 | $69.8 | $73.8 | **$74.9** | $75.6 | $77.9 | $81.9 |
| **WACC 11.09% (new base)** | **$52.2** | **$55.3** | **$58.3** | **$58.9** | **$59.5** | **$61.3** | **$64.3** |
| WACC 12.09% | $48.5 | $51.4 | $54.2 | $54.9 | $55.3 | $57.0 | $59.8 |

vs. $61.49 live → gap = (58.9 − 61.49) / 61.49 = **-4.21% overvalued**, down from +1.4% last run.

### Verdict: **🔴 FLIPS FROM UNDERVALUED (+1.4%) TO OVERVALUED (-4.2%)**
This gap was already the thinnest on the book before the rebuild (+1.4%, explicitly called "effectively fair value" and "a rounding-error call" in the last two reports) — a 59bp Rf move was always going to be enough to flip a model this close to indifference, and it has. No change to the underlying Brent-reversion thesis itself; this is purely a discount-rate effect layered on top of the hedge-decoupling pattern BW has flagged for several reports (XLE's price has not been tracking spot oil closely either way). **Flagging directly for BR's scheduled 10/1 XLE top-up trigger close-out**: whatever BR's formal decision is today, it should be made knowing this desk's valuation support for XLE is now negative, not positive as it was through all of September.

### Key assumption that would reverse both GEHC and XLE's flips
If the 10yr yield reverses back below 5% and the "full week" condition this desk used to justify this rebuild unwinds, both WACCs should roll back toward the prior ~4.70% Rf baseline, which would restore GEHC to roughly +7% undervalued and XLE to roughly +1% undervalued — these two flips are the least robust calls in this report precisely because the underlying gaps were already thin before the rate move. NVDA and OMCL's verdicts are far more rate-robust; even a full reversal would not flip either name's direction.

---

## 7. Micron Technology (MU) — GS's #1 pick, not held — hard pass confirmed, now wider

Full first build remains this desk's 9/30 report (FY27-31 FCF table, memory-cycle margin-correction assumption, all five key-assumption caveats — unchanged, full detail in git history). This run applies the same WACC rebuild treatment for consistency with the four held names, since the same risk-free-rate move applies to every discount rate on this desk's book, not only the held ones.

**WACC sensitivity (rebuilt row in bold; g = 3% throughout):**

| | g = 2% | g = 3% (base) | g = 4% |
|---|---|---|---|
| WACC 11.09% | ~$607 | **$656** | ~$712 |
| **WACC 12.59% (new base)** | **$501** | **$654** | ... see note |
| WACC 14.09% | ~$435 | ~$565 | ~$613 |

(Column consistency note: this desk's original MU grid's g=2%/4% corner cells were interpolated approximations, not full recomputations, per the 9/30 report's own disclosure — the g=3% row is the only fully exact column and is what this verdict is based on.)

**Price-data caveat (consistent with GS's, JPM's, and BW's own flags this week):** WebSearch this run again returned a wide, inconsistent spread for MU's post-print price ($923–$1,150 depending on source/vintage) — the same data-quality problem every desk on this team has now flagged repeatedly. This desk uses state.md's own 10/1 ~09:41 ET read (~$1,054.97) as the most defensible single figure, but the conclusion below does not depend on picking the right number in that range: **even at the low end of the unreliable spread ($923), new fair value $654 implies a gap of roughly -29%** — still a clear, high-confidence overvaluation call.

Gap at state.md's reference price: (654 − 1,054.97) / 1,054.97 = **-38.00% overvalued**, wider than the pre-rebuild -34.7%.

### Verdict: **OVERVALUED, gap ≈ -38%. Hard pass confirmed, now with a wider margin than before the print or the rate move.**
Not investable at any price in the currently-circulating range. The rate move makes an already-wide-margin pass wider still — this is the opposite of a case where rising rates would ever flip MU positive.

---

## Cross-check with GS screener (analysts/gs-stock-screener.md, 2026-10-01 report)

GS's rank-1 stays on **MU** this run (print digested, reaction "genuinely unsettled," explicitly framed as "watch, don't chase") — consistent with this desk's own read; no disagreement on direction, same hard-pass conclusion from two different frameworks (GS's relative-multiple screen vs. this desk's absolute intrinsic-value build). **GS's #2 is GEHC**, framed as "still the only name on this sheet trading below this book's own intrinsic-value estimate" — **this framing is now stale as of this report**; this desk's rebuild flips that specific claim, and GS's next report should be made aware. **GS's #3 is NVDA**, consistent divergence already on file (GS's cheap-forward-multiple case vs. this desk's DCF overvaluation call, now wider). No disagreement on OMCL or XLE's direction from GS this run (GS did not publish a fresh independent view on either today), but this desk's own XLE flip is new information GS has not yet seen.

## Explicit read on trader's current positions (all six held) plus GS's #1 pick

**GEHC**: 🔴 **flips to overvalued, gap ≈ -2.3%** (was +7.1% undervalued) — valuation support for the original entry trigger is gone; flag for BW's rule-14 framework and BR's sizing review.
**XLE**: 🔴 **flips to overvalued, gap ≈ -4.2%** (was +1.4% undervalued) — same rate-driven mechanism; flag directly for BR's scheduled 10/1 top-up-trigger close-out.
**NVDA**: hold, no add, no trim — gap widens to ≈ -16.7% overvalued (was -10.6%), the widest reading on file; flag for BR's scheduled 10/1 pool-target re-underwrite.
**OMCL**: hold, no add — DCF discount narrows to ≈ +43.5% upside (was +56.9%) but remains by far the widest mispricing on the book; DCA gate remains the operative timing mechanism, unaffected in direction.
**VTI / VXUS**: hold, no valuation view — defer to BR/BW.
**MU** (GS's #1 pick, not held): hard pass confirmed, gap widens to ≈ -38.0% (was -34.7%). Not investable regardless of which unreliable post-print price is used.

**Standing flag for the next run:** this rebuild is conditioned on the 10yr holding above 5%. If it reverses, GEHC and XLE's flips are the first things to re-check (their old verdicts were thin enough to flip back on a comparable move the other way); NVDA and OMCL's verdicts are robust to a partial reversal. Absent a rate reversal, the next report should return to normal price-roll cadence unless a company-specific catalyst (earnings, guidance, M&A) warrants a fresh fundamentals rebuild on an individual name.

---

Sources:
- [U.S. 10-year Treasury yield reportedly hits 5.2%, highest since 2007 - Digg](https://digg.com/world-business/yy8sp23a)
- [10 Year Treasury Rate — YCharts](https://ycharts.com/indicators/10_year_treasury_rate)
- [Machine learning algorithm sets Micron stock price for October 1 2026 - Finbold](https://finbold.com/machine-learning-algorithm-sets-micron-stock-price-for-october-1-2026/)
- [Current share price for MU - InvestSMART](https://www.investsmart.com.au/security/nasdaq/mu/micron-technology/share-price)
- [Micron Technology Shares Rebound Following Blowout Q3 Results - Dukascopy](https://www.dukascopy.com/swiss/english/marketwatch/market-News/News/155365/)
- Internal: trading-experiment/state.md (Balance history through 10/1 ~09:41 ET; rate-print chain 9/23-9/30), analysts/gs-stock-screener.md (10/1 report), this desk's own 9/28, 9/29, 9/30 reports (git history) for original WACC/FCF builds and the rebuild-criterion flag
